Q&A – The Paradigm Shift To Continuous Flow Processes: A Holistic View

For pharmaceutical companies trying to optimize their manufacturing, finding a contract development and manufacturing organization (CDMO) capable of operating continuous flow processes at commercial scales is paramount to ensuring their eventual commercial success. To do so requires identifying partners with the expertise, assets, and skills to transition batch processing to continuous flow and scale up dangerous chemistries, as well as further optimize recycling and waste management.

Expertise in dangerous chemistries and continuous flow processes is crucial to ensuring the manufacture of safe, efficacious products while also delivering ecological benefits. In a recent webinar, “The Paradigm Shift to Continuous Flow Processes: A Holistic View,” Dr. Bert Metten, Technology Development Manager at Ajinomoto Bio-Pharma Services, explored Aji Bio-Pharma’s proven expertise and capabilities in handling dangerous chemistries.

At the conclusion of the webinar, Dr. Metten fielded questions on the intricacies of Aji Bio-Pharma’s approach to continuous flow, including its scale up parameters, modeling approaches, and other crucial decisions that impact reactor design and reaction optimization.